Stelara a 130 Mg 130 mg Concentrate for solution for infusion
PDF Leaflet Revision Date: 19 September 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Moderately to severely active Crohn's disease and ulcerative colitis.
Dosage (summary)
Initial IV dose based on weight; 260 mg for u226455 kg, 390 mg for >55 to u226485 kg, 520 mg for >85 kg. First subcutaneous dose at week 8.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Use only if benefits outweigh risks in pregnancy; limited excretion in breast milk.
Key Drug Interactions
- Live vaccines
- Immunosuppressive medicines
Contraindications
- Hypersensitivity to ustekinumab
- Active tuberculosis
Common side effects
- Nasopharyngitis
- Headache
- Fatigue
- Diarrhoea
Counselling Points
- Monitor for signs of infection
- Avoid live vaccines
- Evaluate for tuberculosis before treatment
Serious warnings
- Increased risk of infections
- Potential for malignancies
- Serious hypersensitivity reactions
Important Disclaimer
The Stelara a 130 Mg 130 mg Concentrate for solution for infusion professional information leaflet below is the property of Janssen Pharmaceutica and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
